Здоровье без побочных эффектов - Питер Гётше

Каков уровень иронии на самом высоком уровне фармацевтической промышленности! Говорить о кодексах практики, строгих правилах и строгих руководствах как о панацее для фармы, которая является худшей из всех отраслей промышленности, нарушая закон до такой степени, что превращается в организованную преступность, и убивая тысячи невинных людей! Это не только заговор, это поистине злая шутка. После того как в январе 2013 года на заседании Prescrire в Париже я прочел лекцию о всепроникающей преступности в фармацевтической промышленности32, я побеседовал с Алейном Брейллоном (Alain Braillon), который вдохновил меня закончить книгу карикатурой.

1. Gøtzsche P.C., Hróbjartsson A. Somatostatin analogues for acute bleeding oesophageal varices. Cochrane Database Syst Rev. 2008; 3: CD000193.

2. Frankfurt H. On Bullshit. Princeton, NJ: Princeton University Press; 2005.

3. Godlee F. Editor’s choice: say no to the free lunch. BMJ. 2005 Apr 16.

4. Fugh-Berman A. Doctors must not be lapdogs to drug fi rms. BMJ. 2006; 333: 1027.

5. Grill M. Kranke Geschäfte: wie die Pharmaindustrie uns manipuliert. Hamburg: Rowohlt Verlag; 2007.

6. Nabi G., Cody J.D., Ellis G., et al. Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. Cochrane Database Syst Rev. 2006; 4: CD003781.

7. Andersen N.V. [Gunnar Lose vs. Yamanouchi]. Ugeskr Læger. 2006; 168: 546–9.

8. Andersen N.V. [Gunnar Lose considers the committee on scientifi c dishonesty]. Ugeskr Læger. 2006; 168: 719–21.

9. Chapple C.R., Martinez-Garcia R., Selvaggi L., et al. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol. 2005; 48: 464–70.

10. Jonas U., Rackley R.R. Eur Urol. 2006; 49: 187–8; author reply 188–90.

11. Rasmussen L.I. [Danes suffer from 12 million diseases]. Ugeskr Læger. 2011; 173: 1767.

12. Andersen N.V. [The drug industry increases lobbyism]. Mandag Morgen. 2007 Sep 3: 20–3.

13. Krogsbøll L.T., Jørgensen K.J., Grønhøj Larsen C., et al. General health checks for reducing morbidity and mortality from disease. Cochrane Database Syst Rev. 2012; 10: CD009009.

14. Krogsbøll L.T., Jørgensen K.J., Grønhøj Larsen C., et al. General health checks in adults for reducing morbidity and mortality from disease: Cochrane systematic review and meta-analysis. BMJ. 2012; 345: e7191.

15. Lifestyle intervention in a general population for prevention of ischaemic heart disease. Study record. Available online at: http://clinicaltrials.gov/ct2/results?term=inter99&Search=Search (accessed 3 June 2013).

16. Kvist J. [The possibility of suicide]. Berlingske Tidende. 2002 Nov 3.

17. Getz L., Sigurdsson J.A., Hetlevik I., et al. Estimating the high risk group for cardiovascular disease in the Norwegian HUNT 2 population according to the 2003 European guidelines: modeling study. BMJ. 2005; 331: 551.

18. Getz L., Kirkengen A.L., Hetlevik I., et al. Ethical dilemmas arising from implementation of the European guidelines on cardiovascular disease prevention in clinical practice. A descriptive epidemiological study. Scand J Prim Health Care. 2004; 22: 202–8.

19. Alonso-Coello P., García-Franco A.L., Guyatt G., et al. Drugs for pre-osteoporosis: prevention or disease mongering? BMJ. 2008; 336: 126–9.

20. Abramson J. Overdo$ed America. New York: HarperCollins; 2004.

21. Black D.M., Cummings S.R., Karpf D.B., et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet. 1996; 348: 1535–41.

22. Erviti J. Bisphosphonates: do they prevent or cause bone fractures? Drug and Therapeutics Bulletin of Navarre. 2009; 17: 65–75.

23. Erviti J., Alonso Á., Oliva B., et al. Oral bisphosphonates are associated with increased risk of subtrochanteric and diaphyseal fractures in elderly women: a nested case-control study. BMJ Open. 2013; 3: e002091.

24. Abrahamsen B, Eiken P, Eastell R. Cumulative alendronate dose and the long-term absolute risk of subtrochanteric and diaphyseal femur fractures: a register-based national cohort analysis. J Clin Endocrinol Metab. 2010; 95: 5258–65.

25. Moynihan R., Cassels A. Selling Sickness: how the world’s biggest pharmaceutical companies are turning us all into patients. New York: Nation Books; 2005.

26. Montori V.M., Isley W.L., Guyatt G.H. Waking up from the DREAM of preventing diabetes with drugs. BMJ. 2007; 334: 882–4.

27. Coombes R. Having the last laugh at big pharma. BMJ. 2007; 334: 396–7.

28. HAVIDOL: female testimonial. Available online at: www.youtube.com/watch?v=sQw_cdhXGco.

29. A new epidemic (motivational deficiency disorder). Available online at: www.youtube.com/watch?v=RoppJOtRLe4.

30. Moynihan R. Scientists find new disease: motivational deficiency disorder. BMJ 2006; 332: 745.

31. Whitehead S. Fashionable to criticise the drug industry? BMJ. 2012; 345: e7089.

32. Gøtzsche P.C. Lecture. Efficacité et effets indésirables des produits de santé: données confidentielles ou d’intérêt public? Available online at: www.prescrire.org/Docu/Archive/docus/PiluledOr2013_Conf_Gotzsche.pdf (accessed 8 Feb 2013).